$TCBPW News
Last published 2y ago
- 2y agoTCBPTCBPWTC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'PR NewswireTC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing...
- 3y agoTCBPTCBPWTC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T cell TherapiesPR NewswireEDINBURGH, Scotland, Feb. 21, 2023 /PRNewswire/ -- TC BioPharm(Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform
- 3y agoTCBPTCBPWTC BioPharm Announces New Chair of the Board, Arlene MorrisPR NewswireEDINBURGH, Scotland, Feb. 14, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform
- 3y agoTCBPTCBPWTC BioPharm to Reschedule Shareholder Update Call and WebcastPR NewswireConference Call to be held on Tuesday, February 21st, 2023 at Noon ET EDINBURGH, Scotland, Feb. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP)
- 3y agoTCBPTCBPWTC BioPharm Announces Successful Dosing of Final Patient in ACHIEVE Safety CohortPR NewswirePhase 2B Clinical Trial Evaluating Omnimmune® in AML Patients EDINBURGH, Scotland, Feb. 7, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP)
- 3y agoTCBPTCBPWTC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical DivisionPR NewswireWill oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical
- 3y agoTCBPTCBPWTC BioPharm to Host Shareholder Update CallPR NewswireConference Call to be held on Monday, February 20th, 2023 at 10:00 am ET EDINBURGH, Scotland, Jan. 20, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP)
- 3y agoAZNCRDFCYADRIGL+2Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical TrialsPR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., Jan. 19, 2023 /PRNewswire/ -- Gamma Delta T Cell Therapy represents one of the most promising T Cell therapies in clinical development. The introduction of T
- 3y agoTCBPTCBPWTC BioPharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)PR NewswireEDINBURGH, Scotland, Jan. 19, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), has received written notification from the listing
- 3y agoTCBPTCBPWTC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in OncologyPR NewswireEndeavor to focus on expanding understanding of gamma-delta T cells in oncological settingsEDINBURGH, Scotland, Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company")
- 3y agoTCBPTCBPWTC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder UpdatePR NewswireDosed first three patients within Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia (AML).Complete and near complete responses (morphologic
- 3y agoTCBPTCBPWTC BioPharm Announces Closing of $7.35 Million Private PlacementPR NewswireEDINBURGH, Scotland, Nov. 30, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform
- 3y agoTCBPTCBPWTC BioPharm Announces $7.35 Million Private PlacementPR NewswireEDINBURGH, Scotland, Nov. 28, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform
- 3y agoTCBPTCBPWTC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid LeukemiaPR Newswire3 Patients Dosed in 5 Patient Safety CohortEDINBURGH, Scotland, Nov. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage
- 4y agoTCBPTCBPWTC BioPharm Announces Key Additions to Scientific Advisory Board, Expanding Cell Therapy ExpertisePR NewswireSAB selected to advance new therapeutic trials and strategic partnerships EDINBURGH, Scotland, Oct. 26, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP)
- 4y agoTCBPTCBPWTC BioPharm to Present at Upcoming Investor ConferencesPR NewswireEDINBURGH, Scotland, Oct. 3, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, tod
- 4y agoTCBPTCBPWTC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune®PR NewswireEDINBURGH, Scotland, Sept. 13, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer to
- 4y agoTCBPTCBPWTC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment ConferencePR NewswireEDINBURGH, Scotland, Aug. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer tre
- 4y agoTCBPTCBPWTC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies SummitPR NewswireEvent Taking Place in Boston on July 26-28, 2022 EDINBURGH, Scotland, July 25, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform all
- 4y agoTCBPTCBPWTC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022"PR NewswireManagement will Participate in Fireside Chat on TC BioPharm's Journey as a Successful CGT Startup on July 13, 2022 EDINBURGH, Scotland., July 8, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBP
- 4y agoTCBPTCBPWTC Biopharm Announces Closing of $4 Million Underwritten Public OfferingPR NewswireEDINBURGH, Scotland, June 7, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer indi
- 4y agoTCBPTCBPWTC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise GloballyPR NewswireEDINBURGH, Scotland, May 31, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer trea
- 4y agoTCBPTCBPWKuick Research Recognizes TC BioPharm as a Key Player in the Gamma-Delta T Cell Therapy MarketPR NewswireSector is Expected to Surpass $4 Billion by 2028 Report Highlights Promising Therapy and Rising Investment from Pharmaceutical Companies EDINBURGH, Scotland, May 23, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NA
- 4y agoTCBPTCBPWTC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy ExpertsPR NewswireDr. Mark Bonyhadi to spearhead SAB EDINBURGH, Scotland, May 18, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamm
- 4y agoTCBPTCBPWTC BioPharm Invited to Present at LD Micro ConferencePR NewswireEDINBURGH, Scotland, May 3, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and v
- 4y agoTCBPTCBPWTC BioPharm to Participate in Upcoming ConferencesPR NewswireEDINBURGH, Scotland, April 26, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer an
- 4y agoTCBPTCBPWTC BioPharm Receives CryoTC® Trademark for Proprietary Cell Freezing ProcessPR Newswire6-month shelf-life milestone achieved Successful thaw of highly activated Gamma delta cells EDINBURGH, Scotland, April 6, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage
- 4y agoTCBPTCBPWTC BioPharm Announces Initiation of Equity Analyst Coverage by EF Hutton with a "Buy" RecommendationPR NewswireEDINBURGH, Scotland, March 29, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer an
- 4y agoTCBPTCBPWTC BioPharm Receives MHRA and Research Ethics Committee Approvals to Initiate Phase 2B/3 Clinical Trials for the Treatment of Acute Myeloid LeukemiaPR NewswireTrial enrollment expected to begin during the first half of 2022 EDINBURGH, Scotland, March 23, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company deve
- 4y agoTCBPTCBPWTC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune®PR NewswireAllogeneic unmodified Gamma Delta product can be stored frozen and used as an 'off-the-shelf' cell therapy EDINBURGH, Scotland, March 17, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW),
- 4y agoTCBPTCBPWTC Biopharm Updates Intellectual Property PortfolioPR NewswireEDINBURGH, Scotland, March 15, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer a
- 4y agoTCBPTCBPWTC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T CellsPR NewswireEDINBURGH, Scotland, March 8, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and
- 4y agoTCBPTCBPWTC Biopharm to Host Corporate Update Call on March 8thPR NewswireEDINBURGH, Scotland, March 2, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer an
- 4y agoTCBPTCBPWTC Biopharm Announces Appointment of New Board MembersPR NewswireEDINBURGH, Scotland, Feb. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer an
- 4y agoTCBPTCBPWTC Biopharm Announces Closing of $17.5 Million Initial Public OfferingPR NewswireEDINBURGH, Scotland, Feb. 15, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer an
- 4y agoTCBPTCBPWTC Biopharm Announces Pricing of Upsized $17.5 Million Initial Public Offering and Nasdaq ListingPR NewswireEDINBURGH, Scotland, Feb. 10, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and